Clinicopathological characteristics, long-term prognosis and follow-up recommendations of primary and secondary cutaneous angiosarcoma: A Danish nationwide population-based cohort study

Kiya Abebe*, Ida Wulff, Katrine Voss Thorsen, Anne Lene Wagenblast, Grethe Schmidt, David Hebbelstrup Jensen, Christina Enciso Holm, Michael M. Petersen, Anand C. Loya, Thomas Mentzel, Mikkel Herly, Mathias Ørholt, Peter Vester-Glowinski

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Background: The prognostic impact of subclassifying tumors as primary and secondary cutaneous angiosarcoma (cAS) in terms of the risk of local recurrence, metastasis, disease-specific mortality, and overall survival has not been extensively investigated in previous studies. This study aimed to characterize the clinicopathological features and estimate the 2-, 5-, and 10-year rates of local recurrence, metastasis, disease-specific death, and overall survival for patients with primary and secondary cAS, and to propose a follow-up recommendation for these patients. Methods: All Danish patients diagnosed with cAS between 2000 and 2023 were included. The prognosis was estimated using age- and sex-standardized stratified cause-specific Cox-regression with all-cause mortality as a competing risk. Results: A total of 192 patients were included, comprising 99 patients with primary cAS and 93 with secondary cAS. The 5-year local recurrence rate was similar between primary (42 %) and secondary cAS (39 %). However, patients with primary cAS exhibited a higher 5-year rate of metastasis (50 %) compared to those with secondary cAS (33 %). Similarly, the 5-year disease-specific mortality was substantially higher in patients with primary cAS (57 %) compared to secondary cAS (35 %). Correspondingly, the 5-year overall survival rate was low in both primary (32 %) and secondary cAS (49 %). Conclusion: Primary cAS is associated with poorer 5-year outcomes of metastasis, disease-specific death, and overall survival compared with secondary cAS. Follow-up could be limited to 5 years, as >95 % of the relapses occurred within this period and may include clinical examinations and local MRI to detect local recurrences, and cross-sectional imaging to detect regional and distant metastases.

Original languageEnglish
Article number109680
JournalEuropean Journal of Surgical Oncology
Volume51
Issue number6
Number of pages42
ISSN0748-7983
DOIs
Publication statusPublished - 2025

Bibliographical note

Publisher Copyright:
© 2025 The Authors

Keywords

  • Adjuvant therapy
  • C-Myc amplification
  • C-Myc positivity
  • Cancer
  • Chemotherapy
  • Clinicopathologic
  • Cohort study
  • Cutaneous angiosarcoma
  • Dermal tumors
  • Dermatology
  • Dermatopathology
  • Disease progression
  • Disease-specific mortality
  • Disease-specific survival
  • Epidemiology
  • Follow-up
  • Follow-up guideline
  • General dermatology
  • Immunotherapy
  • Incidence
  • Local recurrence
  • Lymphedema
  • Lymphedema-associated angiosarcoma
  • Metastasis
  • Nationwide
  • Oncology
  • Overall survival
  • Pathology
  • Patient outcomes
  • Population-based
  • Primary angiosarcoma
  • Prognosis
  • Prognostic factors
  • Radiation-induced angiosarcoma
  • Radiotherapy
  • Retrospective
  • Sarcoma
  • Secondary angiosarcoma
  • Skin cancer
  • Soft tissue
  • Subcutaneous tumors
  • Surgery
  • Surgical treatment

Cite this